Remove Disease Remove Events Remove Licensing
article thumbnail

Protein degraders: chasing undruggable targets

BioPharma Drive: Drug Pricing

Published July 8, 2025 Gwendolyn Wu Senior reporter post share post print email license Proteasomes are cellular machines for breaking down proteins. Love Employee via Getty Images For decades now, scientists have been experimenting with a new way to target and destroy proteins linked to disease. You can unsubscribe at anytime.

article thumbnail

Otsuka’s Sibeprenlimab Shows Significant Proteinuria Reduction in Phase 3 IgAN Trial

The Pharma Data

Proteinuria reduction is a well-established surrogate marker for the progression of kidney disease, and this level of decline is considered both statistically significant and clinically meaningful in slowing disease progression toward end-stage kidney disease (ESKD). Treatment-emergent adverse events (TEAEs) occurred in 76.3%

Trials 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema

The Pharma Data

Durable Benefit and Positive Clinical Outcomes “Today’s results underscore the promising potential of Intellia’s approach to genome-editing therapy — a one-time treatment that has been well tolerated and offers a highly differentiated, durable effect for patients suffering from a serious disease,” said John Leonard, M.D.,

article thumbnail

Biogen Launches Phase 3 Trial of Felzartamab for Primary Membranous Nephropathy

The Pharma Data

Primary membranous nephropathy is a rare and serious autoimmune kidney disease characterized by the formation of autoantibodies that damage the glomerular basement membrane, often resulting in nephrotic syndrome —a condition marked by high levels of protein in the urine, severe swelling, and a significant risk of progression to kidney failure.

Trials 40
article thumbnail

Microbiological Applications: Bacterial Metabolism | BMG LABTECH

BMG Labtech

Improved understanding Understanding metabolism is also crucial for drug discovery and investigating disease mechanisms. The ability to measure reactive oxygen species can provide important information on, for example, cell signaling events including those that take place in bacteria and other cells. and Hinshelwood, C.

article thumbnail

The future of mental health treatment: Zelquistinel’s role

Drug Target Review

By adjusting the activity of this receptor, these drugs can influence brain functions associated with mood, cognition and pain, positioning them as potential treatments for conditions like depression, cognitive disorders and neurological diseases. “We call this phenomenon ‘event-driven pharmacology.”

article thumbnail

Navigating Regulatory Hurdles in Drug Development

DrugBank

As clinical development progresses, pharmaceutical companies must submit periodic updates to regulatory agencies, reporting on patient safety data, adverse events, and protocol modifications. Once a drug completes Phase III trials, companies prepare a New Drug Application or Biologics License Application (BLA) for final review.